Texas family is first to sue GSK over Avandia
The widow and son of a man from Beaumont, Texas, USA, are suing UK drug major GlaxoSmithKline based on claims that the popular diabetes drug Avandia (rosiglitazone) contributed to his fatal heart attack.
The law suit, filed in the US District Court for the Eastern District of Texas, is one of the first against the pharmaceutical giant since a May 21, report linked Avandia use to an increased risk of heart attack in patients using it (Marketletter June 11).
60-year-old Larry Alan Stanford died from a heart attack the same day as the report was published in the New England Journal of Medicine warning of Avandia dangers. Mr Stanford had taken Avandamet, a form of Avandia's mixed with another diabetes drug, since early 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze